FDA Approves BESREMi for Adults with Essential Thrombocythemia

The US Food and Drug Administration (FDA) has approved ropeginterferon alfa-2b-njft (BESREMi) for adults with essential thrombocythemia (ET). This regulatory milestone establishes ropeginterferon alfa-2b-njft as the very first FDA-approved therapeutic option for ET in nearly three decades. The approval covers adults with ET regardless of their specific driver mutation genotype or previous disease status, including newly diagnosed patients who are completely naive to cytoreductive therapy.

Previously, ropeginterferon alfa-2b-njft was commercially available in the United States under an orphan drug designation for treating polycythemia vera (PV). This expansion of the product label into ET addresses a critical, long-standing gap in myeloproliferative neoplasm (MPN) clinical care.

Key Takeaways for Oncology Nurses: Core Clinical Rationale

To support patient care and clinical integration, oncology nurses should master these foundational elements of ET and its mechanism:

• The Pathological Threat: Essential thrombocythemia is a rare, chronic clonal blood cancer and myeloproliferative neoplasm characterized by the clonal overproduction of platelets in the bone marrow, frequently driven by somatic genetic mutations such as the JAK2 mutation.
• Systemic Complications: Because of elevated platelets, patients remain at ongoing risk for serious, life-threatening vascular complications, including myocardial infarction (heart attack), stroke, pulmonary embolism, deep vein thrombosis, abnormal bleeding, and splenomegaly.
• Mechanism of Action: Traditional cytoreductive agents primarily focus on lowering peripheral blood counts and controlling symptoms with minimal impact on disease biology. In contrast, ropeginterferon alfa-2b-njft is a long-acting interferon-based therapy utilizing novel monopegylation technology and an extended half-life. It is engineered to target disease-driving progenitor cells directly at the source in the bone marrow while lowering elevated platelet counts and reducing overall disease burden.

Clinical Evidence: The SURPASS ET Study

The FDA approval was supported by robust efficacy and safety data from the global Phase 3 SURPASS ET randomized clinical trial (NCT04285086). The multicenter, active-controlled study evaluated the efficacy and durability of ropeginterferon alfa-2b-njft in adult patients with ET.

In the trial, ropeginterferon alfa-2b-njft demonstrated superior clinical performance compared to anagrelide, a standard cytoreductive agent. Patients treated with the novel interferon achieved significantly higher rates of durable modified European Leukemia Net (ELN) responses and sustained hematologic control. Furthermore, treatment with ropeginterferon alfa-2b-njft was associated with a notable reduction in thromboembolic events over the 12-month evaluation period.

Principal investigator Dr. Ruben Mesa, M.D., President of Advocate Health's Cancer National Service Line, highlighted the clinical paradigm shift in a news release: "The approval of BESREMi provides an important new treatment option that is supported by strong clinical evidence and that also works at the source of the disease rather than solely managing symptoms."

Key Takeaways for Oncology Nurses: Safety and Patient Care

Given the complex pharmacological profile of interferon alfa products, oncology nurses are central to ensuring patient safety, managing toxicities, and maintaining treatment adherence. Nurses should focus on the following parameters:

• Boxed Warning Vigilance: Ropeginterferon alfa-2b-njft carries a Boxed Warning highlighting that interferon alfa products can cause or aggravate severe, potentially fatal neuropsychiatric, autoimmune, ischemic, and infectious disorders.
• Contraindication Screening: Do not administer this therapy to patients with a history of severe depression, active suicidal ideation, suicide attempts, moderate or severe hepatic impairment, untreated or active serious autoimmune diseases, or transplantation.
• Blood Count Monitoring: Because the drug can cause myelosuppression, monitor patient complete blood counts (CBC) at baseline, every 2 weeks during titration, and every 3 to 6 months during maintenance.
• Multisystem Side-Effect Management: Educate patients on potential toxicities and establish monitoring plans:
  • Endocrine: Monitor TSH and discontinue if endocrine toxicities occur that cannot be medically managed.
  • Ophthalmologic: Advise patients to have eye examinations before and during treatment; evaluate any visual symptoms promptly.
  • Hepatic and Renal: Evaluate liver enzymes, hepatic function, and serum creatinine at baseline and during therapy.
  • Cardiovascular: Avoid use in patients with unstable or severe acute cardiovascular disease, and monitor those with a history of cardiovascular disorders.
  • Dental and Oral: Advise patients on good oral hygiene and regular dental examinations to mitigate dental and periodontal toxicities.
  • Gastrointestinal: Discontinue therapy if clinical signs of pancreatitis or colitis develop, and monitor serum triglycerides before and intermittently during treatment.
  • Neuropsychiatric: Conduct continuous assessments for depression, mood changes, or suicidal ideation.

Reference

1. FDA Approves PharmaEssentia's BESREMi® (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia, A Rare Blood Cancer. Press Release. Burlington, Mass: PharmaEssentia USA Corporation; August 31, 2026. Accessed August 31, 2026.